RxDoctor Payments Data

Rowena Achin, MD

Internal Medicine · Las Vegas, NVNPI 1366467888

Payments from drug & device makers

$5,954in general payments, 2019–2025

Across 331 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$746
  • Lilly USA, LLC$590
  • Bayer$510
  • Amgen$392
  • Pfizer$336
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$5,954100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,954 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$269,759
Medicare patients
396
Services billed
2,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$88,126
JardianceEmpagliflozin67$85,822
MounjaroTirzepatide39$47,946
EliquisApixaban37$44,267
FarxigaDapagliflozin Propanediol21$30,893
XareltoRivaroxaban24$26,019
JanuviaSitagliptin Phosphate17$23,505
TrulicityDulaglutide21$19,582
LinzessLinaclotide11$17,638
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$11,620
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$7,171
Clonidine18$4,135
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen121$4,000
Albuterol Sulfate HfaAlbuterol Sulfate74$3,964
Atorvastatin Calcium403$3,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$746$88,12675 claims
Boehringer IngelheimJardiance$46$85,82267 claims
Lilly USA, LLCMounjaro, Trulicity$590$67,52860 claims
PfizerEliquis$336$44,26737 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,091$42,51334 claims
Johnson & JohnsonXarelto$34$26,01924 claims
AbbVieLinzess, Synthroid$52$18,62228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →